Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | EED | O75530 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6414235 | 1.00 | PDK2 (0.46) | PDK2MAPTSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL6410761 | 0.92 | MAPT (0.43) | PDK2MAPTSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL6404504 | 0.91 | PDK2 (0.48) | PDK2MAPTSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL6404511 | 0.91 | PDK2 (0.48) | PDK2MAPTSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL4963056 | 0.90 | RORC (0.37) | PDK2NPY5RRORC | |
| SCHEMBL4963061 | 0.90 | RORC (0.37) | PDK2NPY5RRORC | |
| SCHEMBL4963131 | 0.84 | PDK2 (0.44) | PDK2MAPTSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL4964952 | 0.83 | PDK2 (0.45) | PDK2MAPTSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL4964877 | 0.83 | PDK2 (0.45) | PDK2MAPTSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL4962318 | 0.76 | MAPT (0.47) | PDK2MAPTSMN1; SMN2L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | claimed |
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | PDK2 1025/4885MAPT 3691/4885SMN1; SMN2 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.